Total Cost
Free shipping on all orders

Powered by GeniusRx

brand simbrinza 1%-0.2% eye drops

In stock Manufacturer ALCON/NOVARTIS 00065414727
$176.00 / 8 Milliliters Drop Btl

Select Quantity

Prescription is required


Ocular Hypertension and Glaucoma

Brinzolamide ophthalmic suspension is used topically to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension. Safety and efficacy of brinzolamide were evaluated in several randomized active- and placebo-controlled studies. In these studies, brinzolamide was as effective as dorzolamide in reducing IOP in patients with glaucoma or ocular hypertension; brinzolamide was less effective than timolol in reducing IOP. Tolerance to brinzolamide apparently does not occur; the reduction in IOP has been maintained over at least 18 months of brinzolamide therapy. When topical brinzolamide is used in conjunction with a topical β-adrenergic blocking agent (e.g., timolol), the IOP-lowering effects of these agents may be additive. In one study in patients with open-angle glaucoma or ocular hypertension in whom IOP was not adequately controlled with timolol alone, addition of brinzolamide to timolol therapy resulted in further decreases in IOP.

Dosage and Administration


Brinzolamide is applied topically to the eye as an ophthalmic suspension. The suspension should be shaken well prior to use. If the patient is receiving more than one ophthalmic drug, the drugs should be administered at least 10 minutes apart.

For the treatment of glaucoma or ocular hypertension, the usual dosage of brinzolamide is 1 drop of a 1% suspension in the affected eye(s) 3 times daily. If further reduction in IOP is required, another topical agent that lowers IOP may be used in conjunction with brinzolamide.

Special Populations

No special population dosage recommendations at this time.



Known hypersensitivity to brinzolamide or any ingredient in the formulation.



Sulfonamide Sensitivity Reactions

Serious adverse events (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, other blood dyscrasias) associated with sulfonamide therapy are possible. Usual precautions associated with systemic use of sulfonamides apply. Discontinue brinzolamide therapy if serious reactions or signs or symptoms of hypersensitivity occur.

General Precautions


For topical use only. Not for injection or oral use.

Ocular Effects

Effect on corneal endothelium not fully evaluated.

Angle-closure Glaucoma

Not studied in patients with acute angle-closure glaucoma. Acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents.

Specific Populations


Category C. (See Users Guide.)


Brinzolamide is distributed in milk in rats following oral administration. It is not known whether brinzolamide is distributed in human milk following topical application to the eye. Discontinue nursing or the drug, taking into account the importance of the drug to the woman.

Pediatric Use

Safety and efficacy not established in children.

Geriatric Use

No overall differences in safety and efficacy relative to younger adults.

Hepatic Impairment

Not studied in patients with hepatic impairment; use with caution.

Renal Impairment

Not studied in patients with severe renal impairment (creatinine clearance less than 30 mL/minute). Not recommended in such patients, since brinzolamide and its metabolite are excreted mainly by the kidneys.

Common Adverse Effects

Adverse effects reported in 1% or more of patients receiving brinzolamide include blurred vision, taste abnormality (bitter, sour, or unusual taste), blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.

Drug Interactions

Oral Carbonic Anhydrase Inhibitors

Potential pharmacologic interaction (additive systemic effects).


Potential pharmacodynamic interaction. Acid-base disturbances produced by oral carbonic anhydrase inhibitors have been associated with toxicity in some patients receiving high-dose salicylates. (See Drug Interactions in the Carbonic Anhydrase Inhibitors General Statement 52:10 and Drug Interactions: Acidifying and Alkalinizing Agents, in the Salicylates General Statement 28:08.04.24.)

Ocular Hypotensive Agents

Potential pharmacologic interaction (additive IOP-lowering effects).

Write Your Own Review

Your meds on autopilot. Forever.